Bevacizumab improves pathologic response
β
Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B. Thomas; Cathy
π
Article
π
2007
π
John Wiley and Sons
π
English
β 271 KB
## Abstract ## BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidineβplusβoxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. ## METHODS. A total of 105 consecutive patients trea